Exclusivity of Research Project Targets. During the Option Period for each Research Project Target, neither CytomX nor any of its Affiliates shall (a) grant, or seek to grant, any right under any CytomX Technology or Developed IP to any Third Party with respect to such Research Project Target or (b) use any CytomX Technology or Developed IP to Develop (itself or through or with a Third Party) (x) Probodies Targeting such Research Project Target other than EGFR or (y) PDCs Targeting any Research Project Target.
Appears in 4 contracts
Samples: Option and License Agreement (CytomX Therapeutics, Inc.), Option and License Agreement (CytomX Therapeutics, Inc.), Option and License Agreement (CytomX Therapeutics, Inc.)
